IMW 2021 | OPTIMISMM: PVd for lenalidomide-refractory myeloma
Katja Weisel, MD, of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, shares updates from the OPTISMM trial (NCT01734928), a Phase III study which investigated pomalidomide, bortezomib, and dexamethasone (PVd) after one prior line of therapy in patients with relapsed or refractory (R/R) multiple myeloma. Dr Weisel discusses the role of the PVd triplet in second line treatment for patients who are lenalidomide-refractory. Dr Weisel also discusses how the safety profile for PVd at first relapse in R/R myeloma patients was found to be consistent with previous reports, and any treatment related adverse effects (TRAEs) occurred early in the treatment and were managed with dose modifications or appropriate treatment. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Katja Weisel, MD, has received institutional grant support from Amgen, BMS/Celgene, GSK and Sanofi; and has received honoraria from AbbVie, Amgen, Adaptive Biotech, BMS/Celgene, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Takeda and Sanofi.
